查詢結果分析
來源資料
相關文獻
- Heliox-Driven Albuterol Therapy in Severe Persistent Asthma with Acute Exacerbation
- 熱交換器測漏方法
- Airway Hyperreactivity Modulated by Immunotherapy with Denatured Ovalbumin in Ovalbumin-Sensitized Guinea Pigs
- 過敏性氣喘
- 麻杏甘石湯對塵蟍誘發氣喘天竺鼠之影響
- 各年齡層氣喘病人食物過敏率與過敏程度之研究
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- 腎氣丸對塵蟍激發喘天竺鼠呼吸道發炎與免疫之影響
- 如何改善老年人氣喘病的療效
- 小兒氣喘處置之最新發展
頁籤選單縮合
題 名 | Heliox-Driven Albuterol Therapy in Severe Persistent Asthma with Acute Exacerbation=氦氧混合氧驅動下對重度氣喘急性發作病患使用支氣管擴張劑化霧治療時的影響 |
---|---|
作 者 | 李琳; 姜霟霆; 張雅雯; 張學文; 黃裕欽; | 書刊名 | 胸腔醫學 |
卷 期 | 19:3 民93.06 |
頁 次 | 頁178-186 |
分類號 | 415.426 |
關鍵詞 | 氦氣; 氣喘; 最大吐氣流量; 急促指數; 第一秒最大吐氣量; Helium; Bronchial asthma; Peak expiratory flow rate; Dyspnea score; Forced expiratory volume in 1st second; |
語 文 | 英文(English) |
中文摘要 | 過去文獻顯示氦氧混合氣可改善乙型支氣管擴張劑albuterol到肺部的吸收量,但它對臨床氣喘發作者的療效,仍無結論。本文即針對氣喘重度發作病患,分別以氦氧混合氣(實驗組)和氧氣(對照組)驅動albuterol化霧治療後,比較其對支氣管擴張的療效影響的差異。 方法:本文將八十位急性重度氣喘發作病患(FEV1<60%預估值)分成兩組。分成接受兩次以氦氣混合氣(80:20)或氧氣驅動albuterol做化霧治療。所有病患均接受靜脈注射類固醇,在治療前後均收集病患動脈血的氣體分析、血流動力學、肺功能以及急促參數,來比較分別以氦氧混合氣和氧氣驅動albuterol對支氣管擴張療效的差異。 結果:以氦氧混合氣驅動albuterol化霧治療下的氣喘病患組,呈現統計學上明顯較佳的最大吐氣流量比率(實驗組:對照組=44.9±6.1%:38.4±7.8%;p<0.01)以及較佳的急促指數(實驗組:對照組=2.4±1.1:4.0±1.1;p<0.01)。 結論:本文研究顯示,對於重度氣喘發作病患,施予氦氧混合氣驅動支氣管擴張劑之化霧治療可提供一有效的輔助工具。 |
英文摘要 | Background: The helium-oxygen mixture (heliox)-powered nebulizer improves the delivery of albuterol to the peripheral lung, but its role in managing acute asthma attacks, however, remains controversial. Methods: To compare the bronchodilator effect produced by albuterol inhalation delivered by a heliox-powered nebulizer with that by an air-O2-powered nebulizer in severe asthmatics with acute exacerbation, we conducted prospective, double-blinded randomized controlled trial in a tertiary university-affiliated medical center in Taiwan. Eighty severe persistent asthmatics (FEV1<60% predicted) with acute exacerbation were randomized to receive 2 doses of albuterol via a nebulizer driven by air-O2 or heliox (80:20). All patients received intravenous methyl-prednisolone. Arterial blood gas (ABG), hemodynamics, spirometric data, and dyspnea scores were collected before and after albuterol treatments. Results: Patients receiving heliox-driven albuterol had a higher peak expiratory flow rate (PEFR) (heliox vs. air-O2 = 44.9±6.1% vs. 38.4±7.8% after 2nd treatment, p<0.01), and a lower dyspnea score (heliox vs. air-O2 = 2.4±1.1 vs.。4.0±1.1 after the 2nd treatment, p<0.01). Conclusion: We conclude that albuterol delivered by a heliox-driven nebulizer may be a useful adjunct therapy in severe persistent asthmatics with acute exacerbation. |
本系統中英文摘要資訊取自各篇刊載內容。